How I treat von Willebrand disease.
暂无分享,去创建一个
[1] H. Deckmyn,et al. von Willebrand factor to the rescue. , 2009, Blood.
[2] A. Tosetto,et al. A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F Mutation). , 2008 .
[3] J. Goudemand,et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) , 2008, Journal of thrombosis and haemostasis : JTH.
[4] A. Tosetto,et al. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. , 2008, Blood.
[5] A. Tosetto,et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. , 2008, Blood.
[6] B. Yawn,et al. von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA) 1 , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] G. Castaman. Desmopressin for the treatment of haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[8] R. Kadir,et al. Review of quality of life: menorrhagia in women with or without inherited bleeding disorders , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] C. Lee,et al. Pregnancy in carriers of haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] P. Mannucci,et al. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery , 2007, Journal of thrombosis and haemostasis : JTH.
[11] A. Tosetto,et al. How to estimate bleeding risk in mild bleeding disorders , 2007, Journal of thrombosis and haemostasis : JTH.
[12] A. Tosetto,et al. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD) , 2007, Journal of thrombosis and haemostasis : JTH.
[13] O. Panes,et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. , 2007, Haematologica.
[14] A. Tosetto,et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study , 2006, Journal of thrombosis and haemostasis : JTH.
[15] P. Mannucci,et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor , 2006, Journal of thrombosis and haemostasis : JTH.
[16] S. Pavord,et al. The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.
[17] Wolfgang Schramm,et al. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. , 2006, Blood.
[18] J. Goudemand,et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD , 2006, Journal of thrombosis and haemostasis : JTH.
[19] A. Tosetto,et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) , 2006, Journal of thrombosis and haemostasis : JTH.
[20] F. Rodeghiero,et al. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H‐M740I) defect , 2006, Journal of thrombosis and haemostasis : JTH.
[21] A. Tosetto,et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study , 2005, Journal of thrombosis and haemostasis : JTH.
[22] F. Rodeghiero,et al. Provisional criteria for the diagnosis of VWD type 1: on behalf of the ISTH SSC Subcommittee on von Willebrand Factor , 2005, Journal of thrombosis and haemostasis : JTH.
[23] F. Rodeghiero,et al. Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease , 2005, Journal of thrombosis and haemostasis : JTH.
[24] D. Economides,et al. The use of levonorgestrel‐releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders , 2004, BJOG : an international journal of obstetrics and gynaecology.
[25] P. Mannucci. Treatment of von Willebrand's Disease. , 2004, The New England journal of medicine.
[26] G. Dolan,et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[27] M. Laffan,et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[28] P. Mannucci,et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. , 2004, Blood.
[29] J. Sadler,et al. Von Willebrand disease type 1: a diagnosis in search of a disease. , 2003, Blood.
[30] D. Economides,et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo‐controlled crossover study , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[31] P. Mannucci,et al. Guidelines for the diagnosis and management of von Willebrand disease in Italy , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[32] M. Makris,et al. Venous Thrombosis Following the Use of Intermediate Purity FVIII Concentrate to Treat Patients with Von Willebrand’s Disease , 2002, Thrombosis and Haemostasis.
[33] F. Rodeghiero. von Willebrand disease: still an intriguing disorder in the era of molecular medicine , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[34] D. Ginsburg,et al. Getting at the Variable Expressivity of Von Willebrand Disease , 2001, Thrombosis and Haemostasis.
[35] J. Eikenboom,et al. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. , 2001, Best practice & research. Clinical haematology.
[36] C. Leissinger,et al. High‐dose DDAVP intranasal spray (Stimate®) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[37] P. Mannucci. How I treat patients with von Willebrand disease. , 2001, Blood.
[38] P. Mannucci,et al. Impact, Diagnosis and Treatment of von Willebrand Disease , 2000, Thrombosis and Haemostasis.
[39] J. Eikenboom,et al. Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F , 2000, Thrombosis and Haemostasis.
[40] J. Sixma,et al. Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[41] A. Hassett,et al. von Willebrand disease and bleeding in women , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[42] R. Bertina,et al. Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation , 1999, Thrombosis and Haemostasis.
[43] Kadir,et al. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[44] É. Fressinaud,et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. , 1998, Blood.
[45] D. Economides,et al. Frequency of inherited bleeding disorders in women with menorrhagia , 1998, The Lancet.
[46] K. Mohlke,et al. von Willebrand disease and quantitative variation in von Willebrand factor. , 1997, The Journal of laboratory and clinical medicine.
[47] D. Economides,et al. The obstetric experience of carriers of haemophilia , 1997 .
[48] M. Blombäck,et al. On the value of menorrhagia as a predictor for coagulation disorders , 1996, American journal of hematology.
[49] P. Mannucci,et al. Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A , 1996, Thrombosis and Haemostasis.
[50] J. Giddings,et al. Protective effects of ticlopidine and aspirin, administered alone and in combination, on thrombus formation in rat cerebral vessels. , 1996, Haemostasis.
[51] P. Mannucci,et al. Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease , 1995, British journal of haematology.
[52] C. Mazurier,et al. Biological effect of desmopressin in eight patients with type 2n (‘Normandy’) von Willebrand disease , 1994, British journal of haematology.
[53] J. Shults,et al. Prevalence of von Willebrand disease in children: a multiethnic study. , 1993, The Journal of pediatrics.
[54] P. Reitsma,et al. Recessive inheritance of von Willebrand's disease type I , 1993, The Lancet.
[55] P. Mannucci,et al. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. , 1992, Blood.
[56] G. Escolar,et al. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. , 1991, Blood.
[57] J. Higham,et al. Assessment of menstrual blood loss using a pictorial chart , 1990, British journal of obstetrics and gynaecology.
[58] M. Moia,et al. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor , 1989 .
[59] F. Rodeghiero,et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. , 1989, Blood.
[60] Z. Ruggeri,et al. von Willebrand factor and von Willebrand disease. , 1987, Blood.
[61] J. Sixma,et al. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. , 1987, Blood.
[62] W. Marks,et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. , 1987, Blood.
[63] F Rodeghiero,et al. Epidemiological investigation of the prevalence of von Willebrand's disease. , 1987, Blood.
[64] C. Abildgaard,et al. Serial studies in von Willebrand's disease: variability versus "variants" , 1980 .
[65] L. Hallberg,et al. Menstrual Blood Loss–A Population Study , 1966, Acta obstetricia et gynecologica Scandinavica.
[66] J. Goudemand,et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). , 2007, Blood.
[67] L. O'Brien,et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. , 2007, Blood.
[68] A. Srivastava,et al. von Willebrand disease in the developing world. , 2005, Seminars in hematology.
[69] F. Rodeghiero,et al. Treatment of von Willebrand disease. , 2005, Seminars in hematology.
[70] Francesco Rodeghiero,et al. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. , 2003, Haematologica.
[71] A. Girolami,et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. , 2002, Blood.
[72] N. Ciavarella,et al. Use of Recombinant Factor VIla (NovoSeven®) in the Treatment of Two Patients with Type III von Willebrand’s Disease and an inhibitor against von Willebrand Factor , 1996 .
[73] H E Solberg,et al. International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values, and International Committee for Standardization in Haematology (ICSH), Standing Committee on Reference Values. Approved Recommendation (1986) on the theory of re , 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.